CALAVI did not meet the primary endpoint in patients hospitalised with respiratory symptoms of COVID-19
On Nov. 12, 2020, AstraZeneca announced that the CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised…
COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
Fred Hutch began experimental COVID-19 vaccine efficacy trial
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
Mesa Biotech received additional $13 million from HHS to develop 30 minute SARS-CoV-2 & Flu A/Flu B test
On Nov. 6, 2020, Mesa Biotech announced it had been awarded a contract up to $13 million from…
Humanigen announced CRADA agreement with U.S. government to develop lenzilumab for COVID-19
On Nov. 6, 2020, Humanigen announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine
On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…
Novavax announced facility expansion to support global vaccine development
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
COVID-19 pandemic sparked 3D printing engineering innovation
On Nov. 2, 2020, Pacific Northwest National Laboratory (PNNL) announced that in the Spring of 2020, as news…
Patriot Express Travel at BWI, SEATAC required on-site, rapid COVID-19 testing
On Nov. 1, 2020, the U.S. Department of Defense announced the start of rapid, on-site COVID-19 testing for…
HHS and DOD announced $12.7 million contract with InBios to boost US production of rapid COVID-19 tests
On Oct. 30, 2020, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of…
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Non-Profit Research
UC Berkeley launched pop-up lab to monitor Bay Area sewage for COVID-19
On Oct. 29, 2020, UC Berkeley announced that it had launched a new high-throughput pop-up lab – a…
UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax provided phase 3 COVID-19 vaccine clinical development update
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
Evidence review confirmed CDC guidance about infectivity of novel coronavirus
On Oct. 20, 2020, researchers at Oregon Health & Science University (OHSU) and Oregon State University (OSU) reported…
BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response
On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…
Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
NIH RADx initiative advanced six new COVID-19 testing technologies
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
The Nobel Prize in Medicine for 2020 was awarded to Harvey J Alter, Michael Houghton and Charles M Rice
On Oct. 5, 2020, the Nobel Prize in Medicine 2020 was awarded to Harvey J. Alter, Michael Houghton…
Fred Hutch opened COVID-19 clinical research center
On Oct. 5, 2020, the Fred Hutchinson Cancer Research Center announced the opening of the COVID-19 Clinical Research…
Amyris delivered sustainable alternative to shark squalene adjuvant enabling vaccines with no sharks killed
On Oct. 1, 2020, Amyris announced that it has begun delivering samples to pharmaceutical companies of a sustainable…
Hydroxychloroquine showed no benefit in COVID-19 prevention
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…